What are analysts'target prices for Sangamo Therapeutics'stock?
4 equities research analysts have issued 12-month target prices for Sangamo Therapeutics' shares. Their forecasts range from $11.00 to $18.00. On average, they anticipate Sangamo Therapeutics' stock price to reach $14.00 in the next twelve months.
Where can I buy shares of sgmo?
Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Who is the CEO of Sangamo Therapeutics?
Business Wire. Sangamo Therapeutics Appoints Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer Sangamo Therapeutics, Inc. (SGMO), a genomic medicine company, announced today the appointment of Bettina M. Cockroft, MD, MBA, as Senior Vice President and Chief Medical Officer.
What is Sangamo?
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.
Should I buy or sell Sangamo Therapeutics stock right now?
4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There ar...
What is Sangamo Therapeutics' stock price forecast for 2022?
4 Wall Street research analysts have issued 12 month target prices for Sangamo Therapeutics' stock. Their forecasts range from $6.00 to $25.00. On...
How has Sangamo Therapeutics' stock performed in 2022?
Sangamo Therapeutics' stock was trading at $7.50 at the beginning of 2022. Since then, SGMO stock has decreased by 49.9% and is now trading at $3.7...
When is Sangamo Therapeutics' next earnings date?
Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for...
How were Sangamo Therapeutics' earnings last quarter?
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) released its quarterly earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0....
Who are Sangamo Therapeutics' key executives?
Sangamo Therapeutics' management team includes the following people: Dr. Alexander D. Macrae Ch.B , M.B., MRCP, Ph.D., CEO, Pres & Director (Age...
What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?
10 employees have rated Sangamo Therapeutics CEO Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com . Sandy Macrae, M.B., Ch.B., Ph.D. has an appro...
Who are some of Sangamo Therapeutics' key competitors?
Some companies that are related to Sangamo Therapeutics include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regener...
What other stocks do shareholders of Sangamo Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA) ,...
Who sold SGMO stock?
What is Sangamo Therapeutics' stock symbol?
SGMO stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Gary Loeb, Rolf Andrew Ramelmeier, and Saira Ramasastry.
How can I listen to Sangamo Therapeutics' earnings call?
Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."
What other stocks do shareholders of Sangamo Therapeutics own?
Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "2235808".
How much money does Sangamo Therapeutics make?
Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).
What is the P/E ratio of Sangamo Therapeutics?
Sangamo Therapeutics has a market capitalization of $836.17 million and generates $118.19 million in revenue each year. The biopharmaceutical company earns $-121 million in net income (profit) each year or ($1.27) on an earnings per share basis.
Is Sangamo Therapeutics a buy?
The P/E ratio of Sangamo Therapeutics is -7.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
News
Sangamo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Trending Stocks
Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' lives using platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Transparency is our policy. Learn how it impacts everything we do
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
How we make money
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
How we use your personal data
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management.
How we approach editorial content
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
Stock Price Forecast
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.
Analyst Recommendations
The 9 analysts offering 12-month price forecasts for Sangamo Therapeutics Inc have a median target of 22.00, with a high estimate of 30.00 and a low estimate of 6.00. The median estimate represents a +283.94% increase from the last price of 5.73.
